Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients

Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients is a phase 2, interventional study registered as NCT06987734 by Shanghai Pulmonary Hospital, Shanghai, China, with a registry enrolment figure of 25 participants, started 2025-06-19 and due to reach its primary completion in 2027-12-31. Interventions recorded: Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab. Conditions listed: Lung Cancer (NSCLC). Primary outcome: Major Pathological Response. Lung eligibility wording from the registry: "Histologically documented, stage II-IIIA Non-Small Cell Lung Cancer (according to version 9th of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology) and previously untreated". Sites: China. No results are recorded here; the registry entry is the source.